LY2157299
Drug timelines are a Plus or Pro feature.
4 regulatory and trial events tracked for LY2157299, covering 2013-12-04 to 2020-12-02. Get the full timeline:
Most recent: Clinical Trial Update: A Study of LY2157299 in Participants With Advanced Hepatocellular Carcinoma [Phase 2]